Earnings call transcript: Dexcom Q4 2025 beats forecasts, stock dips

robot
Abstract generation in progress

Dexcom (DXCM) reported Q4 2025 earnings exceeding forecasts with an EPS of $0.68 and revenue of $1.26 billion, yet its stock dipped 4.45% in after-hours trading. The company highlighted strong international growth, the launch of the Dexcom G7 15-day system, and anticipates Medicare coverage expansion for new patient segments. Dexcom also provided a robust 2026 revenue guidance between $5.16 billion and $5.25 billion, expecting continued growth driven by product innovation and market expansion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)